title: Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia.
abstract: OBJECTIVE
  To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg.
  
  
  METHODS
  A total of 162 patients were included in this study. Of the patients, 108 were randomized to receive 4 mg doxazosin XL (group 1), and 54 were randomized to receive 8 mg (group 2) treatments. After 1 month of treatment, 31 patients in group 1 whose quality of life (QoL) score was unchanged or had deteriorated were switched to 8 mg doxazosin XL treatment (group 1b).
  
  
  RESULTS
  The mean age was 59.8 years. After 1 month of treatment, the mean alteration in the International Prostate Symptom Score was 3.9 and 5.2 (P = .028), for the maximum urinary flow rate (Q(max)), it was 3.0 and 3.6 mL/s (P = .206), and for the QoL score it was 1.3 and 1.7 (P = .038) in groups 1 and 2, respectively. For group 1b, during the period in which the patients were receiving 4 and 8 mg doxazosin XL treatments; the International Prostate Symptom Score changes were 1.3 and 3.6 (P <.001), the Q(max) changes were 1.6 and 3.2 mL/s (P <.019), and the QoL changes were 0.4 and 1.8 (P <.001) in groups 1 and 2, respectively.
  
  
  CONCLUSIONS
  With no changes in side effects, 8 mg doxazosin XL treatment is an efficient choice for patients who did not have an adequate response to 4 mg doxazosin XL treatment.
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Tanju
authors.initials: T
authors.lastname: Keten
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Aslan
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Melih
authors.initials: M
authors.lastname: Balci
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey. Electronic address: tuncelaltug@yahoo.com.
authors.forename: Altug
authors.initials: A
authors.lastname: Tuncel
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Ovunc
authors.initials: O
authors.lastname: Bilgin
authors.affiliation: Department of Urology, Karatekin Hospital, Cankiri, Turkey.
authors.forename: Cem
authors.initials: C
authors.lastname: Dilmen
authors.affiliation: Department of Urology, Cankiri State Hospital, Cankiri, Turkey.
authors.forename: Umit
authors.initials: U
authors.lastname: Ozdemir
authors.affiliation: Department of Urology, Cankiri State Hospital, Cankiri, Turkey.
authors.forename: Sedat
authors.initials: S
authors.lastname: Yahsi
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Ozer
authors.initials: O
authors.lastname: Guzel
authors.affiliation: Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Atan
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011788:Quality of Life; D017211:Treatment Failure
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D017292:Doxazosin